Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Diagnos Inc (QB)

Diagnos Inc (QB) (DGNOF)

Closed June 23 4:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
0.227 Day's Range 0.241465
0.175 52 Week Range 0.4327
Market Cap
Previous Close
Last Trade
Last Trade Time
Financial Volume
$ 6,296
Average Volume (3m)
Shares Outstanding
Dividend Yield
PE Ratio
Earnings Per Share (EPS)
Net Profit

About Diagnos Inc (QB)

Cmp Integrated Sys Design
Cmp Integrated Sys Design
Quebec City, Quebec, Can
Diagnos Inc (QB) is listed in the Cmp Integrated Sys Design sector of the OTCMarkets with ticker DGNOF. The last closing price for Diagnos (QB) was $0.23. Over the last year, Diagnos (QB) shares have traded in a share price range of $ 0.175 to $ 0.4327.

Diagnos (QB) currently has 76,648,586 shares outstanding. The market capitalization of Diagnos (QB) is $24.53 million. Diagnos (QB) has a price to earnings ratio (PE ratio) of -9.88.

DGNOF Latest News

No news to show yet.
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
AREBAmerican Rebel Holdings Inc
$ 0.76
SHCRSharecare Inc
$ 1.365
NXLNexalin Technologies Inc
$ 1.7499
$ 6.1209
SPECSpectaire Holdings Inc
$ 0.50
FLFVFeutune Light Acquisition Corporation
$ 2.5502
FLFVUFeutune Light Acquisition Corporation
$ 2.75
RWODRedwoods Acquisition Corporation
$ 2.34
KAVLKaival Brands Innovations Group Inc
$ 1.23
RWODURedwoods Acquisition Corporation
$ 3.24
NVDANVIDIA Corporation
$ 126.57
AREBAmerican Rebel Holdings Inc
$ 0.76
SIRISirius XM Holdings Inc
$ 2.94
AAPLApple Inc
$ 207.49
NKLANikola Corporation
$ 0.3466

DGNOF Discussion

View Posts
oldguy oldguy 1 week ago
I am a die hard, just bought more.
oldguy oldguy 8 months ago
I just bought some more.
oldguy oldguy 1 year ago
When every one leaves is when they go up.
oldguy oldguy 1 year ago
Looking a little better.
oldguy oldguy 1 year ago
Nice brake out. But no volume. Maybe it is so good, no one wants to sell.
oldguy oldguy 2 years ago
It is about time. Breaking out. Maybe, just maybe, it is going to work.
oldguy oldguy 2 years ago
Then again, maybe NOT.
oldguy oldguy 2 years ago
It looks like this is coming back to life.
talius talius 3 years ago
DIAGNOS Inc. TSX-V: ADK Increasingly In-play with Two Major Catalysts; Clinical trials on Stroke Predictor have begun at 2nd largest health service provider in USA, and worlds largest eyecare company is in negotiations for platform access. See recent Market Bulletin
talius talius 3 years ago
DIAGNOS' AI-Driven Retinal Analysis Technology is in the Process of Transforming Industries -- DIAGNOS Inc. is the subject of a Technology Marketwatch Journal review, the full copy of which may be viewed at online.

Excerpt copy:
DIAGNOS Inc. (TSX-V: ADK) (OTCQB: DGNOF) (Frankfurt: 4D4) is a Canadian-based medical software technology company that pioneered 'Computer Assisted Retinal Analysis' (CARA), which automatically analyses the retina (located at the back of the eye) using machine learning / artificial intelligence (AI) technology to identify damage caused by diabetes and cardiovascular issues. For the last 7 years DIAGNOS has commercially advanced its first large-scale application of the technology, primarily aimed at preventing diabetic retinopathy. Entering 2022 marks a pivotal time for DIAGNOS as the technology has recently seen several large players in the eyecare sector and medical field commit to large-scale roll-outs, this is putting pressure on others in the sector to consider a similar move and not be left behind. DIAGNOS' technology essentially transforms eyecare centers into Point of Care and wellness diagnostic centers as the CARA platform also is expected to commercially launch several other large-scale applications, including an application for hypertensive retinopathy (launch imminent) and one for stroke prediction (undergoing clinical trials now in USA). Complicated medical conditions resulting from diabetes, high blood pressure, and potential stroke can be detected by DIAGNOS' algorithms able to interpret detailed imagery of the retina. Since New Look (with 407 locations in Canada) signed on for CARA platform roll-out DIAGNOS' phone has been ringing from around the globe, essentially other industry participants do not want to miss out on a technology whose time has come. Look for an increase in new business announcements to come from the DIAGNOS over the coming months and years. In fact, Essilor Luxottica (Euronext Paris Stock exchange: EL), the largest eyecare company in the world, with EUR$16+ Billion in revenue and ~15,000 locations, signed a MOU with DIAGNOS in August-2021 and is in active negotiations on terms -- this alone has massive latent catalyst potential for upside share price revaluation of ADK.V as details emerge. Specifically DIAGNOS and Essilor are currently negotiating 3 things; 1) contract for the existing platform, 2) Essilor wants DIAGNOS to do a specific development for their line of fundus camera, and 3) Essilor wants access to future applications DIAGNOS will roll out. The fact the largest eyecare company in the world chose DIAGNOS' technology speaks volumes as to where this is headed.
With all the activity DIAGNOS has on the go it appears a low-risk high-reward proposition: ADK.V only has 69.12 million shares outstanding, there are very little warrants left, and insiders & family office own ~40% of the outstanding shares. DIAGNOS has no debt, money in the bank, an untapped C$2 million government credit line if needed, has a high-margin SaaS model (it only costs ~4 cents to process an image that it charges between ~C$5 - $10), is expected to be cash flow positive (based on solid contracts) in the coming fiscal year, has numerous new business prospects in discussion now, and is expected to see rapid revenue growth. Astute investors connecting the dots about what is unfolding are apt to do well by establishing a long position in ADK.V now.

DIAGNOS Inc. received its first institutional coverage from the independent investment bank / advisory / equity research firm Echelon Capital Markets, its current rating is 'Top Pick', 'Speculative BUY' with a near-term (12 month) target price per common share of DIAGNOS of $1.55 Canadian (or in US dollars: USD$1.23 or in Euros: €1.09) -- click here to view full copy of their latest report. The original initiating report was exceptionally thorough (~40 pages), the analyst contacted multiple industry participants, and recently (November-2021) sat down for an interview [running time 32 min. Youtube] on his reasoning for making it a top pick entering 2022.
------ ------ ------ ------ ------ ------ ------ ------ ------

Recommend reading:
trader_ron trader_ron 3 years ago
DIAGNOS (TSXV: $ADK) (OTCQB: $DGNOF) (FRA: 4D4A) Announces Date of Annual General and Special Meeting of Shareholders
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
trader_ron trader_ron 3 years ago
Nice little pop to start off the week, DIAGNOS (TSXV: $ADK) (OTCQB: $DGNOF) (FRA: 4D4A) Announces Date of Annual General and Special Meeting of Shareholders
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq

trader_ron trader_ron 3 years ago
$DGNOF News- DIAGNOS signs Memorandum of Understanding with Essilor International.
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq

trader_ron trader_ron 3 years ago
(TSXV: ADK) (OTCQB: DGNOF) (FRA: 4D4A) Market Analysis #UnderValued #Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
trader_ron trader_ron 3 years ago
$DGNOF (TSXV: ADK) – DIAGNOS Announces a Pilot with Opticalia in Spain
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
trader_ron trader_ron 3 years ago
$low n $teady, this is building nicely.
trader_ron trader_ron 3 years ago
News next week? if so we should see a move higher imo
trader_ron trader_ron 3 years ago
You keeping an eye on this, News starting to flow an the PPS is solid, chart reads HIGHER :)
trader_ron trader_ron 3 years ago
$DGNOF – DIAGNOS Announces a Pilot with Opticalia in Spain
#Bloomberg #nyse #healthcare #otcmarkets #investors # #MarketWatch #WallStreetJournal #nasdaq
TrendTrade2016 TrendTrade2016 4 years ago
Beautiful play 34c to 65c fur 2900.00 profit. How much did you make.
Lastly all the s*** that he recommends or Canadian over the counter companies with no business no management no reporting

I haven't seen him right on one of these except for a little blip here in there where he probably sells his stock
Just follow him because everything he recommends goes down it's like the George Costanza episode in Seinfeld where he does the opposite of his initial thoughts just short everything that he recommends
This is a great short I've already shorted two or three others that he's recommended and made 40 to 80%
OptimusPrime555 OptimusPrime555 4 years ago

OptimusPrime555 OptimusPrime555 4 years ago
Heading to no bid soon! Scam company!!!
TrendTrade2016 TrendTrade2016 4 years ago
Keeps going higher and higher
OptimusPrime555 OptimusPrime555 4 years ago
mo_mo mo_mo 4 years ago
Awesome week so far!! Great call TrendTrade2016. You know what you are talking about for sure. I appreciate the honesty- very rare on these boards. Cheers
OptimusPrime555 OptimusPrime555 4 years ago
Heading to NO BID!!!

OptimusPrime555 OptimusPrime555 4 years ago

OptimusPrime555 OptimusPrime555 4 years ago
SCREAMING PUMP and DUMP!! Low volume garbage!!!
TrendTrade2016 TrendTrade2016 4 years ago
monster week will be and learn!!
TrendTrade2016 TrendTrade2016 4 years ago
watch her fly!!!
OptimusPrime555 OptimusPrime555 4 years ago
Too funny! Low volume pump and dump!!!

TrendTrade2016 TrendTrade2016 4 years ago
booom...look at her run....going to be epic...lmao!!
OptimusPrime555 OptimusPrime555 4 years ago
Fake news! SCAM ALERT!!!
OptimusPrime555 OptimusPrime555 4 years ago
Going to get very ugly here! Get ready for tax loss selling!!
OptimusPrime555 OptimusPrime555 4 years ago
PUMP and DUMP!!! REVERSE SPLIT any day!!
TrendTrade2016 TrendTrade2016 4 years ago
Get ready to rumble. Love this company.
TrendTrade2016 TrendTrade2016 4 years ago
ADK.V look out for this Canadian one of a kind AI Computer Assisted Retinal Analysis....FDA approved!!
EddardStock EddardStock 7 years ago
News came out today if anyone is following this here
oldguy oldguy 7 years ago
Your not the only one that feels that way.
WoW!!! ADK.V!!! What are people smoking!!!
I seriously question whether people who swing by this stock and choose to keep it moving have some kind of special mental disability preventing them from pulling their heads from their a55es.

1. Lets see we have a A.I. platform that is:

- ISO 9001:2008 Certified
- ISO 13485:2003 Certified
- Canadian Medical Devices Conformity Assessment System Certified
- Health Canada Approved - Class 2 Medical Device
- FDA Approved - Class 2 Medical Device
- CE Mark Approved

2. We have a guaranteed $15 Million contract with Mexico National health authority over the next 3 years. At $5 Million per year.

3. We have a pilot project with Bayer in Canada that has been going on for over a year.

4. Our Cardio is launching, as we can see from todays news release.

5. We are first movers in both Macular Degeneration and Blindness, along side Cardio Vascular scanning using Artificial Intelligence.

6. Our Algorythm is scoring higher accuracy than IBM's WATSON!!! and GOOGLE's DEEP MIND!!!

7. We are in over 16 countries which will 1000% turn into full long term contracts. As you will understand by the following 3rd party DD.

8. We are making money all over the world in large quantities beyonf Mexico in Saudi Arabia for example.

9. Here is a good Mark Cuban interview:

Here is an excerpt from that interview:


User image

10. Here is an interview with Mark C0ckerbrg from Aug 16th 2016!!! jump to 20:00 for the A.I. talk. Jesussss can the Weed heads, Bltch Chain & Cryptohoes get their shyt together??

Here is a great clip from the latest Joe Rogan Podcast: Click to realize how many diabetics will be in the United States by 2040!!!

But noooooo please buy your fugazy a55 blockchain bs, of which 99% of the companies are shell frauds that will not ever gain 1% of market share. The point of blockchain is that it is open sourced, and everyone needs to be on the same g-damn chain for the data to be accessible by everyone! Thats the whole point!! If everyone is using their own blockchain then the data will be more segregated than it already is uggghhhhhh. Do any of those idiots buying BC stock even know how the tech works!!!! Its meant to be open sourced and FREE to stop middlemen from taking cuts for doing fack all. It is a race to the bottom for the lowest fee BC, what kind of a business model is that?? Dont get me started on ICO's and "most" Cryptos. The world barley functions with 170 currencies now theres a few million digital ones. GTFO.

Anyways. Spread this around if you want. Do yourself a g-damn favor. I started off all cool and calm but my mind is being blown by the lack of awarness for this REAL, MONEY MAKING, A.I., DISRUPTIVE TECH!!!

Reply Quote Add Post To Favorites Follow Post

EddardStock EddardStock 7 years ago
This is very undervalued IMO hoping to get in next week!
oldguy oldguy 7 years ago
I am IN. Bought a bunch.Here is why.

DIAGNOS enters 2017 in new partnership with BAYER Canada, and uses artificial intelligence tool to explore for Monarques Gold Corp.

NEW YORK, NY, January 5, 2016 /Sector Newswire/ -- DIAGNOS Inc. (TSX-V: ADK) (US Listing: DGNOF) last month announced a pilot project contract for diabetic macular edema and diabetic retinopathy screening with BAYER Canada. DIAGNOS is a Canadian-based healthcare software technology company, its 'Computer Assisted Retinal Analysis' (CARA) business applies artificial intelligence in the diabetes market which non-invasively identify patients at risk of vision loss. Additionally, DIAGNOS announced the signing of an agreement for the use of CARDS (Computer Aided Resource Detection Software) to generate mining targets on the Croinor Gold property owned by Monarques Gold Corporation.

DIAGNOS Inc. is expanding globally as a first-mover in the healthcare retinal analysis sector with proprietary disruptive technology whose adoption is quickly gaining momentum, doctors and specialists strongly endorse it as large numbers are non-invasively screened that would otherwise not be seen. ADK.V's revenue growth curve is rapidly accelerating with topline >100% Y/Y. Swiss pharmaceutical giant Novartis has become the Company's biggest customer, initially engaging ADK.V for a series of pilot 'wellness' programs over the last couple years in various countries, paying DIAGNOS to screen patients. Recently Novartis has begun converting pilot programs into contracts, with more on the way due to the overwhelming success in identifying patients that could benefit from Novartis' treatment. German pharmaceutical company Bayer has only recently engaged ADK.V with similar intentions. DIAGNOS recently signed a contract with an unnamed pharmaceutical company targeting the US, the world's largest healthcare market. ADK.V has also started to sell its solutions to governments on a cost-reduction approach, recently signing its first government contract in Mexico. Supported by a strong growth and recurring revenue model, and a low cost growth associated with its artificial intelligence software, we expect shares of ADK.V to rise several multiples higher than its current price near-term.

Fig. 1 Retinal image enhanced with DIAGNOS software, prepped for A.I. auto-detection of pathology & lesion classification.

DIAGNOS' current market cap of ~$14.4 million Canadian (trading at ~$0.11/share) is minuscule compared to where it appears headed based on contracts in hand, momentum, and potential. As the reality of the accomplishments and potential are understood by the marketplace Technology MarketWatch Journal anticipates the share price of ADK.V will move nearer to 50 cents to better reflect its current inherent value. Further below is document compelling projected transaction and revenue numbers; shareholders will appreciate that the Company's fiscal Q3 (ending December-2016) is expected to show profitability (in Q3 ADK.V will have booked revenues of ~$1.15M and expenses of ~900K) and the Company is expected to experience increasingly robust financials going forward. Patient tests per month were ~22,000 this October, are expected to be ~26,000 for November, and are expected to increase to between 60,000 - 70,000 patients per month in 2017. As impressive as those increases in patient tests are, it is only just the beginning. How big will this get? The answer is 'we just don't know', but there are numerous indicators ADK.V is going on a massive run; experts believe there are ~500 million diabetic individuals worldwide (source: WHO) and the Company's adoption growth curve for its technology is very early stage. The Company negotiates its pilots with Pharma so that upfront costs are covered, ensuring it has a big enough commitment so that DIAGNOS rarely needs to spend money up front on incremental business. With four deployment options for its technology, all running at least 55% margin per transaction, ADK.V has impressive revenue projections based on committed contracts alone. Future projections are certain to improve as the level of new inquiries now coming into the Company and discussions regarding new business from big Pharma, governments, hospitals, and clinics world-wide now are off the chart. Often there is lag for new business from initial pilot (dipping their toe) to commitment (full plunge into larger contract), but as DIAGNOS has proved with Novartis and the Government of Mexico -- it's a win-win for everyone to be in business with DIAGNOS. Where this is headed is truly exciting, the long-term strategy for the Company is to eventually shift more toward standalone deployment of its technology (which has highest margins for the Company), with others/partners carrying the operating costs, and DIAGNOS acting as a centralized world-wide cloud-based database/processing center (a secure state-of-the-art facility in Montreal where its software enhances and analyzes retinal images of patients) handling large volumes of transactions.

Excerpt of recent (December 6, 2016) news from DIAGNOS:

BAYER Canada and DIAGNOS join efforts against Diabetes

BROSSARD, QUEBEC--(Marketwired - Dec. 6, 2016) - DIAGNOS Inc. - .("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in applying Artificial Intelligence in healthcare technical services including screening, software and algorithm development, data analysis, and image processing, announces today a pilot project contract for diabetic macular edema and diabetic retinopathy screening with BAYER Canada. Under the terms of the agreement, DIAGNOS will provide a fully turn-key screening service to benefit one thousand diabetic patients in the Toronto area. Screening will be offered to diabetics affiliated to their health entities to test the impact of including preventive screening programs.

According to the International Diabetes Federation, diabetic retinopathy and macular edema are the most common diabetic eye diseases and the leading cause of blindness around the world. It is a treatable disease that, as with most diseases, has a higher treatment success rate in its earlier stages. However, there are generally no symptoms until the disease has progressed to more severe stages, making early detection methods critical by helping the prevention of vision loss.

"The opportunity to partner with Bayer offers an immense advantage at detecting treatable diabetic retinopathy using the advanced Artificial Intelligence technology and eliminating sight-threatening complications of this disease", said Netan Choudhry, MD FRCS(C) DABO, director at DIAGNOS. Mr. André Larente, President of DIAGNOS, added "We are excited to start our new commercial relationship with BAYER in Canada and begin screening for diabetic macular edema and retinopathy. Following the expected success of this project, we intend to expand the scope of services offered through this pharmaceutical company into other countries." here for full copy from source

Excerpt of recent (December 21, 2016) news from DIAGNOS:

Monarques Gold Corp. will use DIAGNOS Artificial Intelligence tools to optimize exploration of Croinor Gold

BROSSARD, QUEBEC--(Marketwired - Dec. 21, 2016) - DIAGNOS Inc. - .("DIAGNOS" or "the Corporation") (TSX VENTURE:ADK), a leader in applying Artificial Intelligence in data mining technical services, announces today the signing of an agreement for the use of CARDS (Computer Aided Resource Detection Software) to generate mining targets on the Croinor Gold property owned by Monarques Gold Corporation ("Monarques") (TSX VENTURE:MQR).

"The use of Artificial Intelligence ("AI") is rapidly growing in all spheres of our lives and the mining exploration sector definitely needs new powerful tools to optimize the use of its capital to discover new mining deposits. The few new discoveries in the mining world is concerning. In 2016, Google, Facebook, Microsoft, IBM have exposed us to AI. Diagnos uses and perfected artificial intelligence since 2000 and is positioned as one of the pioneers in this industry," said Mr. Michel Fontaine, Vice-President, mining of DIAGNOS.

"This agreement will allow us to complement and optimize our drilling campaign, thanks to the powerful algorithms of DIAGNOS on our huge database. Over the years, we have accumulated tons of data. This objective targeting using complex algorithms allows a non-biased geological, statistical and stochastic approach. CARDS will help our geologists optimize geoscience data and identify potential gold-bearing targets in a 2D environment in a short time on our Croinor Gold property," said Mr. Jean-Marc Lacoste, President and CEO of Monarques.

CARDS is a state-of-the-art computer system that uses powerful algorithms to digitally analyse publically available as well as privately owned geological information. For this occurrence, three data mining techniques based on clustering and decision tree will be used in order to generate new targets with a high level of accuracy.

Founded in 1998, DIAGNOS is a publicly traded Canadian corporation with a mission to commercialize technologies combining contextual imaging and traditional data mining thereby improving decision making processes. DIAGNOS offers products, services, and solutions to clients in a variety of fields including healthcare and natural resources. DIAGNOS can count on a multidisciplinary team that includes professionals in geophysics, geology, Artificial Intelligence, mathematics, as well as remote sensing and image interpretation. here for full copy from source

The Company's retinal analysis analysis business was incepted in the wake of the downturn in the mining sector a few years back, DIAGNOS was focused on data analysis in that sector and made the decision to springboard off its platform and expertise in artificial intelligence to build the application it has now in order to fill the gap between doctors and specialists. ~Four years ago the Company launched with zero clients, proved its concept in 2015 and 2016, and is in 12 countries with pharmaceutical companies today (10 countries with Novartis). DIAGNOS just became operational with wellness programs in three new countries (Nigeria, Kenya, and Malaysia) this November-2016.

Besides Novartis and Bayer investing increasingly more capital towards DIAGNOS, the contacts and introductions that have been made by pharmaceutical companies in all those countries to date have themselves created a flurry of new interest in DIAGNOS that is expected to translate to additional opportunity for the Company to expand and gain additional momentum.

Once DIAGNOS is in a country it gets introduced to all the government departments, hospitals, and clinics; DIAGNOS develops its own contact with them. The first major government deal with the Mexican government was recently signed for ADK.V to screen up to 106,000 diabetics by year end. DIAGNOS can now rely on larger monthly revenues. The Latin America market is one of the largest market for this kind of automated analysis of medical images.

Saving vision by reducing congestion at specialists

DIAGNOS sells an automated system to screen patients for eye diseases. Its system takes a pictures of a person's eyes, and then uses an artificial intelligence image-recognition algorithm to assess the patient's risk of over 20 eye diseases. If it detects a risk, it refers the patient to a retinal specialist doctor, who prescribes the appropriate medication or treatment. Because the images can be sent over the internet, the doctor can be in a different physical location confirming the diagnostic.

The diseases targeted by the algorithm include the leading causes of blindness among adults, such as diabetic retinopathy and aged-muscular degeneration. According to the World Health Organization, 347 million people have diabetes worldwide (many experts believe that number is low and actually closer to 500M), of that number 0.1% of people with diabetes will lose their vision completely per year if not screened, that translates to 347,000 people per year that will go blind from a curable disease if they are not screened. These diseases are treatable with existing medicine but only if caught in the early stage. However, people at risk are not getting their eyes checked regularly, and therefore going blind unnecessarily, for the following reasons:

A). There is a shortage of retina specialist doctors. There are just ~1,800 retina specialists in the US versus ~42 million diabetics. Clinical guidelines suggest that every diabetic be screened for diabetic retinopathy once a year, obviously impractical for such a large number to be screened under traditional methods by so few specialists. In less developed countries the ratio of specialists to diabetic population is even worse compared to the US and Canada. By using an algorithm to screen patients, DIAGNOS ensures that only those at risk see a doctor, which relieves congestion in the healthcare system, while improving access to healthcare.

B). Seeing a doctor is expensive. Retina specialists can charge $300 per visit, but DIAGNOS' software driven procedure charges out at only say ~$20 per visit, and this fee can be paid by the pharmaceutical company rather than the patient.

C). Seeing a doctor is inconvenient. Retina specialists tend to be located in urban areas, and therefore may be inaccessible for rural populations. However, DIAGNOS' system could be installed in Primary Care Facilities, or stores such as Walgreens and Wal-Mart, which are beginning to provide low-cost healthcare services, further improving access to basic healthcare. Theranos Inc., an American privately held health technology company which developed a simple blood test that could be deployed in a similar manner, had signed a partnership agreement with Walgreens and ramped up to ~$9 billion valuation (Theranos has since had tech issues and pulled back, unlike Theranos tough DIAGNOS' technology has been able to withstand rigorous vetting). Often there is also a general lack of advertising targeting diabetics as to where they can be tested. Additionally, specialists in some countries are caped by quotas.

Diabetic Retinopathy is a Treatable Disease

Early detection and treatment can prevent 85% to 95% of blindness cases.

The patient may experience no symptoms until the condition is severe.

People who are unscreened are more likely to:
- Present in the ER.
- Become blind.
- Have other complications.

People who are screened tend to take better care of their diabetes.

The Solution: Early screening using artificial intelligence software

DIAGNOS' Computer Assisted Retinal Analysis (CARA) Platform - DIAGNOS already has FDA approval as a medical device. The DIAGNOS solution fills the gap between the doctors and the specialist. Making the general practitioner able to manage vision lost for all diabetic patients by having access to this technology.

Regulatory Compliance:

ISO 9001:2008 Certified
ISO 13485:2003 Certified
Canadian Medical Devices Conformity Assessment System Certified
Health Canada Approved - Class 2 Medical Device
FDA Approved - Class 2 Medical Device
CE Mark Approved

Fig. 4 CARA screening.

DIAGNOS' test is painless and quick, generally taking 2 - 3 minutes maximum, its one flash, the company takes the original image and enhances it to make it easier to read and then the algorithms do the interpretation.

Having artificial intelligence in the loop to take care of a very demanding interpretation task that requires a high degree of proficiency, consistency, and accuracy 24/7 is a great benefit to specialists. DIAGNOS' software can operate at the same high level all day long, where as traditional methods rely upon alertness of humans.

Automatic Detection and Triage

DIAGNOS' algorithms are capable of:
β€’ Automatic detection of pathology in retinal photographs.
β€’ Lesion classification.
β€’ Pre-triaging patients in order of severity.

Figure 5 (above) Automated triage can help reduce healthcare labor requirements while increasing patient access to quality care and reducing healthcare expenditure.

DIAGNOS ends its patient screening session by returning to the patient a copy of the image of their own eye, either by email, or smart phone, or a printed copy. That way they can see inside their own eyes, it makes an impression on the client to be more conscientious of their health. From the patient's perspective screening gives a visual representation of how well someone is managing their diabetes, leading to increased awareness, and increased compliance with diabetes management.


Because people are not being screened regularly, they are losing their vision unnecessarily. This is also a problem for pharmaceutical companies, since they are missing out on drug sales. It is estimated that only 30% of people at risk have their eyes checked on an annual basis. Increasing that rate to 90% would triple the drug sales, while reducing the number of individuals who go blind by 85%. This creates a win-win situation for patients and drug companies. The pharmaceutical companies pay DIAGNOS to screen people, but make their money back through higher sales of their patented drugs.

Value Propositions:

β€’ Convenient non-invasive test.
β€’ Trip to specialist only if necessary.

------ ------ ------ ------ ------ ------

Diabetologist/ GP / Endo
β€’ Higher patient compliance.
β€’ Additional pertinent patient information.

DIAGNOS is aiming to target hospitals and clinics. Putting a camera in a clinic with say 12 doctors operating out of it makes sense; it would allow the doctors to get results on the spot and provide a higher level of care for their patients.

------ ------ ------ ------ ------ ------

Retina Specialist
β€’ Increased focus on treatable cases.
β€’ Increased revenue.

DIAGNOS does not compete with specialist as the Company's algos do not diagnose, they flag patients most at risk with indicators to see the specialist.

------ ------ ------ ------ ------ ------

Pharmaceutical Company
β€’ Increased drug sales volume.

Novartis' main Dibetic Retinopathy drug is Lucentis, Bayer's is EYLEA, specialists inject the drug into the eye. The relationship DIAGNOS has had with Pharma has been developing over the last 2 - 3 years but has only now begun to bloom.

[Note: In Canada the drug companies charge ~C$1,800 for a dose, and once a patient gets under the drug its 4 to 7 times per year and treatment averages for ~4 years.]

------ ------ ------ ------ ------ ------

Insurance Company
β€’ Increased patient compliance.
β€’ Decreased health plan expenditure.

------ ------ ------ ------ ------ ------

β€’ Significant cost avoidance mid/long term.
β€’ Positive political optics.

The old saying "A stitch in time saves nine" rings true. The cost of managing diabetic populations that have not been getting screened properly is exploding. In the case of Mexico, for example, ~7 years ago diabetics took up ~6% of the country's medical budget, now it is ~27% of their medical budget. Fact is, there is not enough money and it is endangering the quality of patient care. DIAGNOS is already working on one program in Mexico, it is so successful that the Company expects another contract which it has begun preliminary work on. Health Services is the largest ministry in Mexico, they take care of >8M diabetics. The Company has been requested to write specifications of service terms (essentially already done as it will the same as the first contract it did). No doubt the Ministry is pleased with DIAGNOS' ability to curb their budget expenses through wellness programs.

DIAGNOS has spreadsheets with analysts in the US, at Medicaid and Medicare, that show the savings simply from preventing diabetics going blind, forget everything else that DIAGNOS can help combat, the Company can save in the state of Florida alone over $6 billion over the next 20 years (Note: DIAGNOS is in proposal stage with Florida at the moment). It is expected that in 2018 Medicaid and Medicare will be establishing new guidelines for screening and are expected to be spending substantial amounts on screening programs. Government involvement with DIAGNOS is the big prize for shareholders; when key news is announced, we anticipate it will act as a major catalyst that will supplant all current projections and cause a dramatic upside revaluation in share price, well above what is being discussed here today.

------ ------ ------ ------ ------ ------

Additional value propositions stem from interaction with a largely uneducated market; retina screening can be used as an opportunity to educate, important since less than 10% of people diagnosed with diabetes are given diabetes self-management training.

Medical Software Has the Mechanics of a Great Business

When mature, DIAGNOS promises to provide investors with a steady stream of recurring revenues, with minimal maintenance capex requirements, three hallmarks of a robust business. The revenues are recurring since people must have their eyes checked annually. Those at risk, such as diabetics and seniors, are stuck with their condition for the rest of their lives, which means decades of repeat sales for DIAGNOS. The sales are reliable because healthcare providers rarely change application software once it becomes ingrained in the system, due to high switching costs. Another strength of DIAGNOS' business model it is scalable and a low marginal cost of growth, a feature common to other application software companies. Since the software is developed upfront, the marginal cost of growth is miniscule, allowing the additional revenue to fall to the bottom line.

Sunny Macro Supports DIAGNOS

A number of macro tailwinds support the technology's adoption. The diabetic population is growing at 10% to 12% per year. The population of seniors and diabetics, two demographics at risk of blindness-causing eye diseases, continue to grow. These two demographics also vote, which incentivizes politicians to see the technology adopted. Companies such as Walgreens and Wal-Mart are looking to offer low-cost healthcare services in their stores, which could be the perfect location for a DIAGNOS' system.

With the number of seniors in the world expected to hit one billion by the end of the decade, charging each $10 to scan the eyes of every senior means the market will be worth $10 billion per year. DIAGNOS generated annualized sales of less than $1 million last year, meaning less than 0.01% of the market has been penetrated. But the company is growing sales at 300% per year, and the rate of test per month is increasing, as shown in the table below.

Company growth on a test basis

Table 1. (Below) Patient tests month over month. Source: Company disclosures.

Note the recent dramatic increases in patient tests month over month; it took a while but all those Pharma pilots are now converting to contracts and growing fast. Patient tests per month were ~22,000 this October, are expected to be ~26,000 for November, and are expected to increase to between 60,000 - 70,000 patients per month in 2017.

Company growth this fiscal year

Table 2. (Below) Revenue 2017 fiscal year. Source: Company disclosures.

The quarterly sales growth rate has increased from the past three quarters. Furthermore, DIAGNOS recently signed a contract with an unnamed pharmaceutical company targeting the US, the world's largest healthcare market. The company also signed its first government contract in Mexico and is looking at Latin America as a large potential market. This suggests the company's sales could be hitting an inflection point, which could see its congestion-relieving software gain the critical mass to be globally adopted.

[*FYI: CARDS stands for 'Computer Aided Resources Detection System', CARDS revenue comes from the remnants of DIAGNOS' mining data analysis business which it is phasing out.]

Company growth year over year including 2018 forecast

Table 3. (Below) Revenue 2015 - 2018. Source: Company disclosures.

DIAGNOS' fiscal year end is in March. DIAGNOS believes it will hit at least $6.6M in CARA revenue for next year, that is a conservative low figure, as depending on what it does in this Q4 the revenues for next year could very easily become $10M or $12M. The growth curve is NOT going to stop as the diabetic population keeps growing and DIAGNOS is so effective at early screening it is quickly now developing a reputation as the best option out there.

NOTE: Right now Bayer is going to be doing a pilot in Canada with DIAGNOS starting in January 2017, they are going to pay DIAGNOS to screen a small population of diabetics to see if what has been observed in other parts of the world are occurring in Canada too. DIAGNOS is confident the results are going to be the same. DIAGNOS currently has a program running with Bayer in Columbia right now. What happens with Bayer is not reflected in the financial projections, however if what occurred with Novatris' pilots is any indication of what to expect then 2018 projections will have yet another revision upwards.

------ ------ ------ ------ ------ ------

Qualitative Points that Support DIAGNOS' Business

While DIAGNOS has a disruptive healthcare technology that looks poised to become a robust business, valuing the Company at such an early stage of adoption for its technology and business model is challenging, especially with the Company only this fiscal Q3 (ending December-2016) demonstrating a turn to profitability. An analysis of qualitative factors provides further support that the shares are due for significant upward revaluation:

1. FDA approval and growing sales to Pharmaceutical imply the technology is effective.

The fact that the FDA has approved the product, and Novartis + Bayer are paying to use it (and are upping their capital investments), confirms that it works.

2. Smart money investors already own a large block of the shares.

Management and friendly shareholders (including Dundee: ~18%, Renauld Family: ~8%, Investment partners NJ: ~8%) own more than 40% of the outstanding shares.

3. No competitors have contracts with pharmaceutical companies and governments.

While some other companies are developing similar software systems, DIAGNOS is the first-to-market and the only one to have a contract with a major pharmaceutical companies and government. The presence of competitors can actually help the adoption of the technology, as other firms will share the cost of developing the market. Since buyers would compare systems anyways, competitors could prove to be advantageous for DIAGNOS.

Note: Competitors have not managed to do what DIAGNOS can do. For example in the US only one other competitor has FDA approval on part of their platform, but they don't have any algorithms to automatically detect the lesions on the retinas (that artificial intelligence is the important piece).

4. First solution for government cost control over diabetes.

By providing an economic model that demonstrates clearly the saving of wellness program or prevention programs, to insure patients don’t go blind and carry the expensive treatment that follows. DIAGNOS has put together the first economic model to help governments curve the cost burden of diabetes.

In contrast to some other names in the healthcare sector, DIAGNOS' management has been more interested in running the business than promoting the stock. With the Company's turn to profitability closing out 2016 and a ramp-up of patient tests on tap, more attention is headed the Company's way, and we expect management will dedicate more resources on responsibly relaying its story to potential investors.

As the company continues to penetrate the >$10Billion dollar market and revenue explodes to the upside, the company will undoubtedly attract more attention from the Pharma companies that sell into that market. ADK.V could be a great tuck-in acquisition for large Pharma companies already selling into the market. Earlier this year, Welch Allyn, an American medical device maker, bought a competitor to DIAGNOS for an undisclosed sum. The acquired company, called Hubble Telemedical, was developing a similar software, but Hubble was a few years behind DIAGNOS (the clear advantage ADK.V has over competition is its proprietary artificial intelligence algorithms).

------ ------ ------ ------ ------ ------

Fig. 6 Eyes tell volumes about cardio vascular health.

DIAGNOS' R&D team is focused on innovation and evolving the platform.

DIAGNOS is working at a new application that will evaluate the risk of cardiovascular issues using the same images as for the retina evaluation.

Future - Cardiovascular: DIAGNOS is working at a new application that will evaluate the risk of cardiovascular issues using the same images as for the retina evaluation. The company is focusing on using its technology to help general doctors in the world by providing real technology tools based on its artificial intelligence platform. Cardiovascular issues are affecting most of the population worldwide. The total market size is $187B in drugs and services.

[FYI: Already 10% of the market for DIAGNOS that is screened now are people that are at risk of being diabetic mainly because they have high blood pressure. If you have high blood pressure and are 60 years old and over, then you are at risk of developing retinopathy.]

------ ------ ------ ------ ------ ------

Sector Newswire has identified the following research links for additional DD on DIAGNOS Inc.:

Company website:

SEDAR filings for DIAGNOS:

Recent Technology Journal Review may be view of DIAGNOS:

This release may contain forward-looking statements regarding future events that involve risk and uncertainties. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual events or results. Articles, excerpts, commentary and reviews herein are for information purposes and are not solicitations to buy or sell any of the securities mentioned. Readers are referred to the terms of use, disclaimer and disclosure located at the above referenced URL(s).

SOURCE: Sector Newswire editorial

Additional Disclaimer and Disclosure I Contact I Terms and Conditions I Copyright I Privacy Policy

StatCounter - Free Web Tracker and Counter
dreambig86 dreambig86 7 years ago
Up 50% in the last week. Nothing but green days ahead with the news release and financials being released soon. Not many companies making a profit at these share price. Check this one out boys
the big guy the big guy 12 years ago
no. watching... there seems to be a glimmer of hope here.. anybody else?
the big guy the big guy 13 years ago
we appear to have some action here. How significant is FDA approval??
the big guy the big guy 13 years ago
no really can't say asiam.... boring
TenaciousD TenaciousD 13 years ago
still playing this at all?

TenaciousD TenaciousD 14 years ago
Full Disclosure. In light of recent events involving the questioning of the integrity of the stock market as a whole as well as the volatility of the American economy and devalued credit rating and dollar I will be selling at least half if not almost all of my holdings by the end of this month and reinvesting in "tangible" holdings. (silver) I will still check in on my favs but won't be around as much. Merry Christmas and Happy New Year to everyone and I hope all of you proper and do well with your present and future endeavors.




Your Recent History

Delayed Upgrade Clock